Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
KN-92 Phosphate, the phosphate salt of KN-92, is an inactive derivative of KN-93. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM). KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cell.
ln Vitro |
LX-2 cell growth is inhibited by KN-93 (5-50 μM; 24 hours), but KN-92 (5-50 μM; 24 hours) is ineffective in preventing cell growth[2]. KN-93, not KN-92, was found to decrease the expression of p53 and p21, according to an analysis of cell cycle regulator expression[2].
|
||
---|---|---|---|
ln Vivo |
|
||
Cell Assay |
Cell Viability Assay[2]
Cell Types: Human hepatic stellate cells (LX-2) Tested Concentrations: 5-50 μM Incubation Duration: 24 hrs (hours) Experimental Results: Ineffective in blocking cell growth. |
||
Animal Protocol |
|
||
References |
[1]. Smyth JT, et al. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002;277(38):35061-35070.
[2]. An P, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13(9):1445-1448. |
Molecular Formula |
C24H28CLN2O7PS
|
|
---|---|---|
Molecular Weight |
554.98
|
|
CAS # |
1135280-28-2
|
|
SMILES |
ClC1C=CC(=CC=1)/C=C/CN(C)CC1=CC=CC=C1NS(C1C=CC(=CC=1)OC)(=O)=O.P(=O)(O)(O)O
|
|
InChi Key |
XRQHWVVDNMJDEQ-IPZCTEOASA-N
|
|
InChi Code |
InChI=1S/C24H25ClN2O3S.H3O4P/c1-27(17-5-6-19-9-11-21(25)12-10-19)18-20-7-3-4-8-24(20)26-31(28,29)23-15-13-22(30-2)14-16-23;1-5(2,3)4/h3-16,26H,17-18H2,1-2H3;(H3,1,2,3,4)/b6-5+;
|
|
Chemical Name |
(E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide phosphate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8019 mL | 9.0093 mL | 18.0187 mL | |
5 mM | 0.3604 mL | 1.8019 mL | 3.6037 mL | |
10 mM | 0.1802 mL | 0.9009 mL | 1.8019 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.